1. Home
  2. RGEN vs AXSM Comparison

RGEN vs AXSM Comparison

Compare RGEN & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Repligen Corporation

RGEN

Repligen Corporation

N/A

Current Price

$113.69

Market Cap

8.1B

Sector

Health Care

ML Signal

N/A

Logo Axsome Therapeutics Inc.

AXSM

Axsome Therapeutics Inc.

N/A

Current Price

$154.10

Market Cap

9.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RGEN
AXSM
Founded
1981
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
9.0B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
RGEN
AXSM
Price
$113.69
$154.10
Analyst Decision
Buy
Strong Buy
Analyst Count
11
17
Target Price
$173.09
$209.18
AVG Volume (30 Days)
788.0K
472.6K
Earning Date
05-27-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
286.96
38.56
EPS
0.86
N/A
Revenue
$141,236,000.00
N/A
Revenue This Year
$14.11
$58.34
Revenue Next Year
$14.71
$54.30
P/E Ratio
$138.80
N/A
Revenue Growth
35.10
N/A
52 Week Low
$102.97
$86.99
52 Week High
$175.77
$191.50

Technical Indicators

Market Signals
Indicator
RGEN
AXSM
Relative Strength Index (RSI) 28.23 30.40
Support Level $113.07 $148.14
Resistance Level $132.51 $191.13
Average True Range (ATR) 6.60 5.49
MACD -0.48 -1.32
Stochastic Oscillator 4.41 6.36

Price Performance

Historical Comparison
RGEN
AXSM

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About AXSM Axsome Therapeutics Inc.

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Share on Social Networks: